Literature DB >> 33651072

Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.

Marijn N Maas1, Jordi C J Hintzen, Philipp M G Löffler, Jasmin Mecinović.   

Abstract

SARS-CoV-2 Spike protein RBD interacts with the hACE2 receptor to initiate cell entry and infection. We set out to develop lactam-based i,i + 4 stapled hACE2 peptides targeting SARS-CoV-2. In vitro screening demonstrates the inhibition of the Spike protein RBD-hACE2 complex formation by the hACE221-55A36K-F40E stapled peptide (IC50: 3.6 μM, Kd: 2.1 μM), suggesting that hACE2 peptidomimetics could form the basis for the development of anti-COVID-19 therapeutics.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33651072     DOI： 10.1039/d0cc08387a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  11 in total

Review 1.  Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.

Authors:  Disha Panchal; Jeena Kataria; Kamiya Patel; Kaytlyn Crowe; Varun Pai; Abdul-Rahman Azizogli; Neil Kadian; Sreya Sanyal; Abhishek Roy; Joseph Dodd-O; Amanda M Acevedo-Jake; Vivek A Kumar
Journal:  Adv Ther (Weinh)       Date:  2021-08-06

2.  Engineering defensin α-helix to produce high-affinity SARS-CoV-2 spike protein binding ligands.

Authors:  Leonardo Antônio Fernandes; Anderson Albino Gomes; Beatriz Gomes Guimarães; Maria de Lourdes Borba Magalhães; Partha Ray; Gustavo Felippe da Silva
Journal:  Protein Sci       Date:  2022-06       Impact factor: 6.993

Review 3.  Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises.

Authors:  Natesh Singh; Bruno O Villoutreix
Journal:  Comput Struct Biotechnol J       Date:  2021-04-26       Impact factor: 7.271

Review 4.  Peptides and peptidomimetics as therapeutic agents for Covid-19.

Authors:  Achyut Dahal; Jafrin Jobayer Sonju; Konstantin G Kousoulas; Seetharama D Jois
Journal:  Pept Sci (Hoboken)       Date:  2021-10-11

Review 5.  Stapled peptides as potential inhibitors of SARS-CoV-2 binding to the hACE2 receptor.

Authors:  Susan Tzotzos
Journal:  J Pept Sci       Date:  2022-02-26       Impact factor: 2.408

6.  Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches.

Authors:  Stanly Paul; Swathi Nadendla; M Elizabeth Sobhia
Journal:  J Phys Chem Lett       Date:  2022-08-05       Impact factor: 6.888

7.  Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.

Authors:  Esley S Santos; Priscila C Silva; Paulo S A Sousa; Cristhyane C Aquino; Gabriella Pacheco; Luiz F L S Teixeira; Alyne R Araujo; Francisca B M Sousa; Romulo O Barros; Ricardo M Ramos; Jefferson A Rocha; Lucas A D Nicolau; Jand V R Medeiros
Journal:  Chem Biol Interact       Date:  2022-09-15       Impact factor: 5.168

8.  Targeting SARS-CoV-2 Receptor Binding Domain with Stapled Peptides: An In Silico Study.

Authors:  Luana Janaína de Campos; Nicholas Y Palermo; Martin Conda-Sheridan
Journal:  J Phys Chem B       Date:  2021-06-11       Impact factor: 2.991

Review 9.  Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions.

Authors:  Pavel V Ershov; Yuri V Mezentsev; Alexis S Ivanov
Journal:  Biomolecules       Date:  2022-01-08

10.  A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.

Authors:  Sajjan Rajpoot; Tomokazu Ohishi; Ashutosh Kumar; Qiuwei Pan; Sreeparna Banerjee; Kam Y J Zhang; Mirza S Baig
Journal:  Drugs R D       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.